Memantine Orion (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at the NMDA receptor, blocking excessive calcium influx caused by prolonged glutamate activity. This mechanism reduces excitotoxicity and helps protect neurons from damage in Alzheimer’s disease.

The dosing regimen for Memantine Orion is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber will set the appropriate dose and titration schedule.

Safety data for memantine in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Memantine Orion, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class for Alzheimer’s disease is acetylcholinesterase inhibitors such as donepezil. While memantine targets glutamatergic excitotoxicity, acetylcholinesterase inhibitors enhance cholinergic transmission. Both classes may be used together for complementary effects, but they act via different mechanisms.

Memantine Orion should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Memantine Orion is administered orally as a tablet. The tablet should be swallowed whole with water and taken with or without food, following the dosing schedule prescribed by the healthcare provider.

Serious risks include seizures, severe allergic reactions such as rash or angioedema, hallucinations or psychotic symptoms, and cardiac arrhythmias. Patients should seek immediate medical attention if any of these events occur.

Memantine Orion is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists.